Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial.
Dafin F MuresanuStefan FlorianVolker HömbergChristian MatulaNicole von SteinbüchelPieter E VosKlaus von WildCodruta BirleIoana MuresanuDana SlavoacaOlivia Verisezan RosuStefan StrilciucJohannes VesterPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2020)
Our trial confirms previous beneficial effects of the multimodal, biological agent Cerebrolysin for overall outcome after moderate to severe TBI, as measured by a multidimensional approach. Study findings must be appraised and aggregated in conjunction with existing literature, as to improve the overall level of insight regarding therapeutic options for TBI patients. The widely used pharmacologic intervention may benefit from a large-scale observational study to map its use and to establish comparative effectiveness in real-world clinical settings.
Keyphrases
- severe traumatic brain injury
- traumatic brain injury
- end stage renal disease
- study protocol
- phase iii
- clinical trial
- newly diagnosed
- randomized controlled trial
- phase ii
- high intensity
- prognostic factors
- peritoneal dialysis
- pain management
- patient reported outcomes
- mild traumatic brain injury
- patient reported
- open label
- high density